Industry News

The collaboration aims to develop an automated, scalable manufacturing platform for gene-modified blood stem cell therapies for sickle cell disease and beta-thalassemia.

The partnership gives SK pharmteco access to Prozomix’s library of more than 6,000 native biocatalysts to support complex active pharmaceutical ingredient synthesis.

The Toyama facility is expected to support monoclonal antibody biosimilar drug substance manufacturing using Cytiva’s standardized, modular bioprocessing technology.

The service uses a structured approach to identify and optimize cell culture media formulations early in development, according to the company.

The collaboration combines sterile fill-finish, autoinjector assembly, and packaging at Thermo Fisher’s site in Ridgefield, New Jersey.

The 68,000-square-foot expansion at its North Augusta site adds commercial-scale synthesis capabilities for complex peptide programs.

The program focuses on optimizing scalable production of monoclonal antibodies for filovirus threats.

The funding supports domestic active pharmaceutical ingredient supply chains for essential hospital medicines propofol and metoprolol.

The funding supports research and development, production expansion and localized radioligand therapy supply.

The expansion at Newark site will add large-scale reactor capacity for small molecules and peptides.

The investment adds high-potency containment and supports amorphous solid dispersion capabilities at its site in Celrà, Girona.

The second phase expands the total investment in U.S. operations to $15 million and targets finished-dose capacity at sites in Texas and Colorado.

The agreement adds to rising global demand for CDMO partnerships and may drive further capacity expansion, according to the company.

The investment supports a three-unit strategy spanning small molecules, peptides, and advanced therapies at sites in the U.S. and France.

The planned Philadelphia facility, combined with operations in Everett, Washington, is expected to boost isotope production capacity 20-fold by 2029.

The Rosenberg site upgrade targets growing demand for U.S.-based liquid and semi-solid drug manufacturing.

The new R&D hub is designed to streamline scale-up and simplify technology transfer for high-potency active pharmaceutical ingredients.

The collaboration focuses on transitioning manual regulatory T-cell manufacturing to a closed, scalable platform.

The new high-pressure technology is designed to improve reaction control, scalability, and safety for active pharmaceutical ingredient manufacturing.

The system is designed to increase manufacturing output while reducing costs and addressing key scalability bottlenecks, according to the company.

The facility will host up to 30 early-stage biotech companies and support drug development and manufacturing collaboration.

The funding will support development of a digital platform designed to model and optimize genomic medicine production.

The investment in Valanx Biotech targets site-specific conjugation technology designed to improve uniformity and stability of antibody-drug conjugates.

The newly approved facility is designed to support late-stage and commercial-scale viral vector production for cell and gene therapy programs.

The agreement supports development and clinical manufacturing of induced pluripotent stem cell-derived therapies targeting ocular and retinal diseases.

First announced in July 2025, the new Research Triangle Park site will provide formulation, analytical, and drug product development services for biopharma clients.

The investment aims to build local oral drug manufacturing capacity and support production of the investigational GLP-1 therapy orforglipron.

The collaboration supports controlled human infection model studies aimed at accelerating RSV vaccine development.

The project will expand plasma-derived therapy production capacity and add at least 300 jobs at the company’s Kankakee manufacturing site.

The extended agreement will increase manufacturing capacity in Houston to support demand for the approved Zynteglo beta-thalassemia gene therapy.